You dont need to be obese to start a GLP-1. In practice, though, you doat least according to the US Food and Drug Administration, which has only approved GLP-1 drugs for people with clinical obesity or Type 2 diabetes and for people who are overweight with weight-related comorbidities
Gastrointestinal side effects, including nausea and vomiting, were also a major factor in treatment cessation
This albumin binding acts as a reservoir, releasing the active peptide slowly over time
Fatigue affects a significant percentage of users, particularly in the early weeks
GLP-1 medications for weight loss (with and without diabetes) While GLP-1 medications were originally developed to treat type 2 diabetes, it has become clear that their effects on appetite regulation and satiety can lead to substantial weight loss even in people who do not have diabetes
GLP-1 agonists reduce albuminuria (protein in the urine, a marker of kidney damage) and appear to slow the progression of diabetic kidney disease
,aspect=ignore)
